April 1, 2019 / 5:08 AM / 22 days ago

BRIEF-Roche: Ipatasertib, Tecentriq Show Promising Results in Early Phase Trial

April 1 (Reuters) - Roche Holding AG:

* ROCHE'S IPATASERTIB IN COMBINATION WITH TECENTRIQ AND CHEMOTHERAPY SHOWS PROMISING ANTI-TUMOUR ACTIVITY IN TRIPLE-NEGATIVE BREAST CANCER IN EARLY PHASE TRIAL Source text: [bit.ly/2uBNHQb] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below